Abstract: Disclosed herein are kits and methods for assessing the risk of poor reading performance in an individual by detecting and identifying single nucleotide polymorphisms in chromosome 19, e.g. in the KIAA0355 (GARRE1) gene. Also disclosed herein are risk alleles in chromosome 19 that are associated with a latent measure for reading ability.

Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.

Abstract: The present disclosure provides a fluidic device including (a) a first channel including a first inlet and a first outlet, (b) a second channel including a second inlet and a second outlet, wherein the second inlet of the second channel is in fluid communication with the first outlet of the first channel, and (c) a sensor positioned between the first outlet and the second inlet, wherein the sensor includes a sensor configured to deflect in response to a flow between the first channel and the second channel.

Abstract: Provided herein are patient-controlled oral liquid-medicine dispenser and deactivation systems. The system includes a dosing container having a defined volumetric capacity and a spillway adapted and configured to allow fluid in excess of the defined volumetric capacity to flow out of the dosing container; a sealed and tamperproof waste receptacle fluidly coupled to the dosing container, the waste receptacle adapted and configured to capture and prevent diversion of liquid medicine dispensed in excess of the defined volumetric capacity of the dosing container; and a suction apparatus extending between a lower region of the dosing container and outside of the dosing container. Also provided herein are methods of administering a medication using the system.

Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.

Abstract: The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide.

Abstract: The present disclosure provides compositions and methods comprising stabilized IL-18 polypeptides for use in therapeutic and non-therapeutic applications. In some cases, the stabilized IL-18 proteins provide IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP. Also provide are methods of administration and methods for making active polypeptides.

Abstract: Compositions and methods of use thereof for delivering nucleic acid cargo into cells are provided. The compositions typically include (a) a 3E10 monoclonal antibody or an antigen binding, cell-penetrating fragment thereof; a monovalent, divalent, or multivalent single chain variable fragment (scFv); or a diabody; or humanized form or variant thereof, and (b) a nucleic acid cargo including, for example, a nucleic acid encoding a polypeptide, a functional nucleic acid, a nucleic acid encoding a functional nucleic acid, or a combination thereof. Elements (a) and (b) are typically non-covalently linked to form a complex.

Abstract: In one embodiment, the present invention is directed to a composition comprising an aqueous or ethanolic extract of at least one herb selected from the group consisting of Aloe barbadensis (:F3), Rheum palmatum L. (:B6), Stephania tetrandra (:C4), Phellodendron chinense Schneid. (:D8), Euphorbia humifusa (:S6), Eclipta prostrata (:I2), A. venetum L. (:F1), Portulaca oleracea L. (:F5), and Sanguisorba officinalis L. (:E5), Camellia sinensis var. assamica (Mast.) Kitamura (:PE) and Punica granatum. (:PG), and mixtures thereof. The composition is administered to a patient, in an effective amount, in a method of treating, inhibiting, preventing, reducing the incidence of, ameliorating or resolving a disease state or condition caused in part or exacerbated by hyperactivity of the androgen receptor (AR), by inhibiting the androgen receptor protein. These compositions may also be used inhibit or stabilize hair loss or grow hair in a subject in need.

Abstract: The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Abstract: The present invention includes compositions and methods for promoting scarless genome editing in a cell. In one aspect, methods of the invention utilize the CRISPR/Cas9 system to introduce a cut site into a genomic location to be edited. In another aspect, methods of the invention integrate an edited sequence into that genomic location in a scarless manner.

Abstract: The disclosure relates to genetically modified bacteria, genetically modified arthropods, and methods for controlling and/or reducing arthropod populations.

Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

Abstract: Systems and methods for formal verification of programs. The systems and methods provide a new game-theoretical, strategy-based compositional semantic model for concurrency, a set of formal linking theorems for composing multithreaded and multicore concurrent layers, and a compiler that supports certified thread-safe compilation and linking. Verification of an overlay interface can include determining an intermediate strategy for a primitive operation running on an underlay interface and refining that intermediate strategy to a strategy running on the overlay interface by applying a vertical and a horizontal composition rule. The refined strategy can then be composed with compatible strategies running on the overlay interface according to a parallel composition rule. Strategies may be compatible when rely conditions imposed by each strategy satisfy guarantees provided by the other strategies. The system and method of formal verification can be applied to formal verification of smart contracts.

Abstract: Poly(amine-co-ester) polymers, methods of forming active agent-load polyplexes and particles therefrom, and methods of using them for delivery of nucleic acid agents with optimal uptake have been developed. Examples demonstrate critical molecular weights in combination with exposed carboxylic and/or hydroxyl groups, and methods of making. Typically, the compositions are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the compositions are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

Abstract: This application relates to methods and kits for treating ARID1A-mutant tumors, cancers, or aberrantly proliferating cells and subjects harboring the tumors, cancers, or aberrantly proliferating cells. In particular, the methods provided include administering to the subject or cell an effective amount of a pyrimidine synthesis inhibitor and administering to the subject or cell an effective amount of a DNA repair inhibitor. The kits include a) a composition comprising a pyrimidine synthesis inhibitor and b) a composition comprising a DNA repair inhibitor.

Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Abstract: Non-naturally occurring tRNASec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNASec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNASec a recombinant expression system, such as E. coli, with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNASec.

Abstract: Parametrically pumped four-wave mixing is a key building block for many developments in the field of superconducting quantum information processing. However, undesired frequency shifts such as Kerr, cross-Ken and Stark shifts inherent with four-wave mixing, lead to difficulties in tuning up the desired parametric processes and, for certain applications, severely limit the fidelities of the resulting operations. Some embodiments include a Josephson four-wave mixing device consisting of a SQUID transmon coupled to a half-flux biased SNAIL transmon, a.k.a. capacitively shunted flux qubit. When the two transmon have matching frequencies, an interference effect cancels the negative Kerr of the SQUID transmon with the positive Kerr of the SNAIL transmon while preserving parametric four-wave mixing capabilities.

Abstract: The present disclosure relates to computer generated topographies from computer correlations of neurobehavioral phenotype mapping data and gene expression mapping data. Neurobehavioral phenotype mapping data is obtained for a selected phenotype and correlated with gene expression mapping data for one or more genes to define a phenotype-gene pair topography for each phenotype-gene pair. A score for each phenotype-gene pair is determined based on the correlation. The scores are used to identify genes, or drug targets, associated with the respective gene of the respective phenotype-gene pair. Conversely, gene expression mapping data is obtained for a selected gene and correlated with neurobehavioral phenotype mapping data for one or more phenotypes to define a gene-phenotype topography for each gene-phenotype pair. A score for each gene-phenotype pair is determined based on the correlation. The scores are used to identify a phenotype associated with the respective phenotype-gene pair.